Cantuzumab mertansine
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | MUC1 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
400010-39-1  |
| ChemSpider | none |
| UNII |
7Z7EUX7R6M |
 (what is this?) (verify) | |
Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate used to treat colorectal cancer and other types of cancer.[1] It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1).[2]
Mechanism
After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.[3]
Clinical trials
Three phase I clinical studies had reported results by 2003.[4]
See also
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Cantuzumab mertansine, American Medical Association.
- ↑ Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Rodon et al. 2008
- ↑ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004
- ↑ http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-newsArticle&ID=354351&highlight=
This article is issued from Wikipedia - version of the 8/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.